

GLIA-CTN Pilot Project Award FY27 Request for Applications

I. Award Purpose

The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN) is an NIH-funded consortium of institutions, clinicians, scientists, and patient advocacy leaders working together to promote advances in the diagnosis and treatment of leukodystrophies. GLIA-CTN is affiliated with Rare Disease Clinical Research Network (RDCRN), which was founded by the NIH Office of Rare Diseases in 2003 and is now coordinated by the National Center for Advancing Translational Sciences (NCATS).

The GLIA-CTN Pilot Project Award is an NIH-funded award that will allow a junior investigator to generate preliminary research data needed to secure more substantial funding through traditional federal, institutional, and/or industry grant mechanisms. Recognizing the importance of creating a sustainable infrastructure for collaborative research and excellence in clinical care, the GLIA-CTN Pilot Project Award is designed to enhance clinical trial readiness in the leukodystrophies through clinical/translational research in biomarkers, or assays to assess therapeutics, or other initiatives directed towards clinical trial readiness.


Projects addressing existing gaps in therapeutic development will be highly valued. Examples include development of new biomarkers for therapeutic engagement in disorders with emerging therapeutic approaches, or new biomarkers for toxicity of established therapeutics in the leukodystrophies.

Projects must be performed using patient samples, imaging, and/or clinical data, leveraging resources provided by the GLIA-CTN. We ask that prospective applicants contact the GLIA-CTN Career Development Committee prior to submission of a new application to confirm that a proposal is responsive to the overall funding structure of the Rare Disease Clinical Research Network (RDCRN) prior to submission.

II. Application Deadline

Applications are currently being accepted on a rolling basis.





III. Number of Awards

At least two GLIA-CTN Pilot Project Awards will be funded annually. Additional awards may be granted during a single funding period at the discretion of the GLIA-CTN Career Development Committee, and as permitted by available funding.

IV. Award Period

Support will be provided for a **one-year** project beginning no later than September 1, 2026.

V. Level of Support

The GLIA-CTN Pilot Project Award will provide **up to \$15,000** for research and salary, inclusive of appropriate fringe and indirect costs. We recommend that the applicant ask for a waiver of indirect costs. No greater than 8% indirect costs are permitted.


VI. Eligibility Criteria

Candidates for the award must have a doctoral degree within the health professions (e.g., MD, DO, DDS, DMD, OD, DC, PharmD) and be actively affiliated with a US-based academic and/or health care institution. Individuals with degrees in nursing research and/or practice, who are licensed to practice clinically, may be eligible. There are also certain circumstances in which individuals with a PhD may be eligible, outlined below.

Innovative, early-stage applications addressing key knowledge gaps that are without evidence of alternate means of funding (i.e., “high-risk/high-yield”) are encouraged.

Eligible applications will meet the following key criteria.

- i. The application must relate to a specific established leukodystrophy ([Vanderver et al., Mol Genet Metab. 2015; doi: 10.1016/j.ymgme.2015.01.006](#));
- ii. All projects must be performed using patient samples, imaging or clinical data. Please contact the GLIA-CTN to assess that the funding proposal is responsive to the overall funding structure of the Rare Disease Clinical Research Network prior to submission;
- iii. The applicant must demonstrate willingness to collaborate with the GLIA-CTN in a sustainable way, including adoption of centralized/standardized data collection tools managed by the GLIA-CTN Biomedical Informatics and Statistical Core (BISC);



- iv. Applicants holding a PhD only must demonstrate integration with the clinical team at their site.
- v. The applicant must describe scientific methods that demonstrate adequate rigor and replication to translate the proposed research project into future clinical studies (i.e., description of alternative approaches or “Go/No-Go” criteria).

Applications should also meet the following feasibility criteria.

- i. The applicant must demonstrate approval by their local Institutional Review Board (IRB) and, if appropriate, their Institutional Animal Care and Use Committees (IACUC) prior to accepting award funding.
- ii. For projects involving interventional approaches, the application must include a protocol synopsis and evidence of submission to appropriate regulatory bodies prior to submission.

VII. International Applicants


Please note that this time, only **US-based investigators are eligible to apply** for funding through a GLIA-CTN Pilot Project Award. We hope to be able to include international applicants in future award cycles. In the meantime, alternative funding mechanisms may be available to support international researchers interested in proposing a new project or collaborating on an existing project within one of the key disease areas outlined in **Appendix A**.

We invite you to contact the GLIA-CTN Administrative Director, Omar Sherbini, MPH, at email@theglia.org or 215-590-3068 for additional details.

VIII. Resource Utilization

Applications that include a plan to leverage central GLIA-CTN resources in one or more of the following ways will be prioritized:

- Use of existing phenotype and longitudinal natural history previously collected through the consortium’s central repository, known as the Myelin Disorders Biorepository Project (MDBP);
- Use of banked and/or prospectively collected biospecimen obtained by one or more clinical research centers currently participating in the GLIA-CTN;



- Inclusion of one or more GLIA-CTN Principal and/or Site Investigators in project design and/or execution;
- Interaction with and/or support from disease-specific patient advocacy organization(s).

IX. Reporting Requirements

- A progress report will be expected at six (6) months following award, and a final report will be expected at twelve (12) months following award.
- Funds will be disbursed within thirty (30) days of the project start date;
- Publication in the form of an abstract at a national or international meeting or submission of a manuscript for publication is expected within twelve (12) months of completion of the award.
- The awardee is expected to attend, and be prepared to discuss their career development project, at the GLIA-CTN Annual Investigator Meeting (Summer 2026), and attend the next GLIA Scientific Meeting (Spring 2027) after completion of their award.

X. Data Sharing Requirements

IRB/IACUC protocols must include language that permits protected health information (PHI) to be shared with the Children's Hospital of Philadelphia (CHOP), and with the Rare Diseases Clinical Research Network (RDCRN) Data Management and Coordinating Center (DMCC) designated by the National Institutes of Health.


XI. Suggested Application Structure

- **Project Proposal (2-3 Pages):** Background, Innovation, Approach (inc. Specific Aims, Preliminary Data and Methods), Project Timeline, and Future Directions;
- **Bibliography**
- **Biosketch***

*In standard NIH format per <https://grants.nih.gov/grants/forms/biosketch.htm>.

XII. Review Criteria

- Does the application meet the eligibility requirements?
- Have efforts been made to connect with leaders in advocacy organization(s) related to the disease(s) of focus in the application, or is there a clearly outlined plan to do so?



- Are the aims well defined?
- Is the approach innovative?
- Are the methods appropriate?
- Will the collected data answer the stated aims?
- Is the budget adequate and the timeline realistic?
- Is this project expected to enhance clinical trial implementation in the near future?

XIII. Review Process

All applications will undergo the following **two-stage** process.

- Applicants will submit a first-round application for review by the GLIA-CTN Career Development Committee. Feedback will be provided to all applicants.
- Applicants with strong proposals will be invited to incorporate the Committee's feedback and submit a revised application for a second round of review.


XIV. Disorders/Topics of Interest

Proposals focused on leukodystrophies listed in Appendix A will be given priority. Applicants interested in conditions not included on the list below should contact the GLIA-CTN Career Development Committee before submitting a new application.

XV. Questions

Questions regarding the application requirements, submission guidelines, etc. may be directed to GLIA-CTN Administrative Director, Omar Sherbini, MPH at email@theglia.org or 215-590-3068.





GLOBAL
LEUKODYSTROPHY
INITIATIVE

A Rare Diseases
Clinical Research
Network Consortium

The Global Leukodystrophy Initiative
Clinical Trials Network (GLIA-CTN)
3615 Civic Center Blvd. ARC 516H
Philadelphia, PA 19104

Appendix A - FY27 Career Development Award Areas of Interest

Adult-Onset Autosomal Dominant Leukodystrophy (ADLD)	Leukoencephalopathy with Calcification and Cysts (LCC)
Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN)	Metachromatic Leukodystrophy (MLD)
Aicardi-Goutières Syndrome (AGS)	Multiple Sulfatase Deficiency (MSD)
Adult-Onset Leukoencephalopathy w/Axonal Spheroids and Pigmented Glia (ALSP)	Pelizaeus-Merzbacher Disease (PMD)
Alexander Disease	Pelizaeus-Merzbacher-Like Disease (PMLD)
Canavan Disease	Pol III-related Leukodystrophy (4H)
Krabbe Disease	TUBB4A-related Leukodystrophy
Leukoencephalopathy w/Brain Stem and Spinal Cord Involvement and Lactate Elevation (LBSL)	Vanishing White Matter Disease (VWM)

The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN) is a member of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research and National Center for Advancing Translational Sciences. The GLIA-CTN is funded under grant number U54NS115052.

